📈 Primary Prevention Engine: Evaluates the absolute 10-year risk of primary atherosclerotic cardiovascular disease (myocardial infarction or stroke) in patients aged 40–79 without established ASCVD.
1. Demographics
2. Biomarkers & History
📚 Pathway Architecture & Clinical Pearls
1. The Pooled Cohort Equations (PCE)
This engine utilises the ACC/AHA Pooled Cohort Equations to predict the absolute 10-year risk of a first hard ASCVD event (nonfatal myocardial infarction, CHD death, or fatal/nonfatal stroke). It serves as the foundational step for primary prevention lipid management.
⚠ The LDL-C ≥ 190 Trap
Do not use this algorithm if the patient has a baseline LDL-C ≥ 190 mg/dL. These patients have presumed familial hypercholesterolaemia and mandate immediate high-intensity statin therapy regardless of their calculated 10-year risk.
2. Indian Context: The South Asian Risk Enhancer
LAI Guidelines Warning: The standard PCE historically underestimates risk in patients of South Asian descent by up to 20-30%. The Lipid Association of India (LAI) considers South Asian ancestry an independent risk-enhancing factor. Indians develop CAD a decade earlier than Western cohorts. Therefore, aggressive lipid lowering is often favoured at lower absolute threshold percentages.
3. Pathophysiology: The Diabetic Mandate
For patients aged 40-75 with Diabetes Mellitus, the decision to start a statin is already made by the guidelines (moderate-intensity minimum). Pathophysiology: Diabetes accelerates atherosclerosis through the formation of advanced glycation end-products (AGEs), increased oxidative stress, and endothelial dysfunction, rendering the vasculature highly susceptible to lipid deposition. The PCE score is strictly used to determine if they need escalation to a high-intensity statin (if 10-year risk is ≥20%).
ACC/AHA Primary Prevention Thresholds
Risk Category
10-Year Risk
Clinical Recommendation
Low Risk
< 5%
Emphasise lifestyle. Statin not typically recommended.
Borderline Risk
5% to <7.5%
Consider moderate-intensity statin if risk enhancers present.
Intermediate Risk
7.5% to <20%
Initiate moderate-intensity statin (reduce LDL-C by ≥30%).
High Risk
≥ 20%
Initiate high-intensity statin (reduce LDL-C by ≥50%).
ASCVD Risk-Enhancing Factors
The presence of these factors strongly favours statin initiation in patients at Borderline or Intermediate risk:
Patient History: Family history of premature ASCVD (males <55, females <65); South Asian ancestry.
Clinical Conditions: Metabolic syndrome; Chronic Kidney Disease (eGFR 15-59); Chronic inflammatory conditions (Rheumatoid arthritis, psoriasis, HIV); History of premature menopause or pre-eclampsia.
